HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.

Abstract
Thyroid cancer is the most common endocrine malignancy with increasing incidence worldwide.The majority of thyroid cancer cases are well differentiated with favorable outcome. However, undifferentiated thyroid cancers are one of the most lethal human malignancies because of their invasiveness, metastatization and refractoriness even to the most recently developed therapies.In this study we show for the first time a significant hyperactivation of ROCK/HDAC6 pathway in thyroid cancer tissues, and its negative correlation with p53 DNA binding ability.We demonstrate that a small compound, SP600125 (SP), is able to induce cell death selectively in undifferentiated thyroid cancer cell lines by specifically acting on the pathogenic pathways of cancer development. In detail, SP acts on the ROCK/HDAC6 pathway involved in dedifferentiation and invasiveness of undifferentiated human cancers, by restoring its physiological activity level. As main consequence, cancer cell migration is inhibited and, at the same time, cell death is induced through the mitotic catastrophe. Moreover, SP exerts a preferential action on the mutant p53 by increasing its DNA binding ability. In TP53-mutant cells that survive mitotic catastrophe this process results in p21 induction and eventually lead to premature senescence. In conclusion, SP has been proved to be able to simultaneously block cell replication and migration, the two main processes involved in cancer development and dissemination, making it an ideal candidate for developing new drugs against anaplastic thyroid cancer.
AuthorsElisa Stellaria Grassi, Valeria Vezzoli, Irene Negri, Árpád Lábadi, Laura Fugazzola, Giovanni Vitale, Luca Persani
JournalOncotarget (Oncotarget) Vol. 6 Issue 34 Pg. 36383-99 (Nov 03 2015) ISSN: 1949-2553 [Electronic] United States
PMID26415230 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anthracenes
  • Protein Kinase Inhibitors
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • pyrazolanthrone
  • rho-Associated Kinases
  • HDAC6 protein, human
  • Histone Deacetylase 6
  • Histone Deacetylases
Topics
  • Anthracenes (pharmacology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Histone Deacetylase 6
  • Histone Deacetylases (metabolism)
  • Humans
  • Protein Kinase Inhibitors (pharmacology)
  • Signal Transduction (drug effects)
  • Thyroid Neoplasms (drug therapy, enzymology, metabolism, pathology)
  • Tumor Suppressor Protein p53 (metabolism)
  • rho-Associated Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: